Report: VC funding for European biotech is gaining strength Venture capital investment in the European biotech industry continues to gain momentum, according to a BioWorld Snapshots report. Private biotech firms globally secured nearly $1.3 billion in venture capital funding in the second quarter of 2013, up 190% from the previous quarter. European firms accounted for 44% of deals. "Maybe you could describe the U.S. market as a tsunami and Europe as a rising tide, but it's growing and it's growing steadily," analyst Jim Healy said. Reuters (8/7)  | Report Track & Traceability
Commerce in Motion and JDA, surveyed 130 quality control, supply chain and operations professionals. The goal was to understand their ability to effectively track, trace, and recall products. Per the study financial cost is the greatest risk associated with the inability to trace items. Download the free report now to see where the Life Sciences industry stands on traceability. |
 | Bavarian Nordic's smallpox vaccine wins EC approval The European Commission granted Bavarian Nordic approval to market the third-generation smallpox vaccine Imvanex. The approval is a first for the Danish vaccine-maker. Imvanex, which is in late-stage development in the U.S., can be used by patients with HIV, atopic dermatitis and others with weakened immune systems. BioWorld (free content) (8/7) Quidel's pregnancy test wins FDA clearance The FDA has cleared Quidel to market its Sofia hCG fluorescent immunoassay, which runs on the company's Sofia Analyzer. The test is used to spot high levels of human chorionic gonadotropin, which signals whether a patient is in early stages of pregnancy, and takes less than three minutes to generate results, the company says. Pharmaceutical Business Review Online (8/6) House bill would lengthen drug combo exclusivity Rep. Jason Chaffetz, R-Utah, introduced legislation that would authorize the FDA to award five-year exclusivity to new drug combinations that contain previously approved active ingredients. "The purpose of the legislation is to provide additional incentives for the creation of new therapeutic combination drugs consisting of previously approved active ingredients," according to a spokeswoman for Chaffetz. PharmaLive.com/Pharmalot blog (8/6) | Acceleron Pharma files for $74.75M IPO Blood cancer and orphan disease drug developer Acceleron Pharma has filed for an initial public offering of stock that could raise up to $74.75 million. The FDA has granted orphan drug designation for the biopharmaceutical company's ACE-536 drug candidate, a potential treatment for anemia related to myelodysplastic syndrome and beta thalassemia, Acceleron said. Xconomy/Boston (8/7)  | EvaluatePharma World Preview 2013, Outlook to 2018
In this sixth annual edition report, Evaluate brings together many of our analyses to provide top level insight into the expected performance of the industry between now and 2018. The report highlights trends in Rx drug sales, patent risk, R&D spend and sales by therapy area as well as a brief review of 2012 performance. Download your complimentary report now. |
 | Ensemble, Novartis unite to develop drugs for autoimmune diseases Ensemble Therapeutics and Novartis will collaborate in the development of Ensemble's investigational inhibitors of the interleukin-17 protein, a target for several autoimmune disorders. The firms also will use Ensemble's drug discovery technology to co-develop small molecule drugs against targets chosen by Novartis. The deal includes upfront and milestone fees plus sales royalties. PharmaTimes (U.K.) (8/7) | 4 biotech crops are being developed in Ghana The Crops Research Institute in Ghana is working on biotech cotton, sweet potato with high protein content, and rice that is salt-resistant and efficient in its use of water and nitrogen. The Savanna Agricultural Research Institute is developing a biotech cowpea. The cotton and rice varieties are being tested in field trials. Ag Professional online (8/7) | | Industrial & Environmental | EPA releases final RFS goals for 2013 The Environmental Protection Agency has finalized the Renewable Fuel Standard targets for 2013, holding steady its overall goal of 16.55 billion gallons while extending the deadline for compliance to June 30. The EPA slashed the target for cellulosic biofuel from a proposed 14 million gallons to 6 million gallons and pledged to ease next year's overall target from the proposed 18.15 billion gallons. BIO welcomed the release of the final targets. "This is a pivotal year for cellulosic and advanced biofuels," said Brent Erickson, BIO's Industrial and Environmental Section executive vice president. "The visible progress of the industry is proof that the renewable fuel standard works," Erickson added. EthanolProducer.com (8/6), Bloomberg Businessweek (8/6), The Hill/RegWatch blog (8/6), DomesticFuel.com (8/6) |  | Tomorrow is always fresh, with no mistakes in it." -- Lucy Maud Montgomery, Canadian author | | | The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com. | Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
| Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | |
No comments:
Post a Comment